Literature DB >> 25684473

Hormone receptor expression and clinicopathologic features in male and female breast cancer.

Fatemeh Homaei Shandiz1, Aliraz Tavassoli, Nourieh Sharifi, Sima Ardalan Khales, Sima Kadkhodayan, Sahar Ardalan Khales.   

Abstract

BACKGROUND: Male and female breast cancers were investigated for variation in the clinicopathologic characteristics and expression of steroid hormone receptors in the northeast of Iran.
MATERIALS AND METHODS: Tumor specimens of 17 males and 338 females with breast cancer were collected at the hospitals of Mashhad University of Medical Sciences. Immunohistochemical expression of hormone receptors and clinicopathologic features of breast cancer were compared between two groups.
RESULTS: The mean age in men was 15 years higher than women (p=0.000). Males and females were mainly in stage II and III respectively (p=0.007). Although more than 60% of male and female patients were grade II, the respective figures for grade I and III were 25% and 12.5% in men but 7.1% and 27.2% in women respectively (p=0.025). ER was significantly more positive in men against women; 82.3% versus 53.4% (p=0.016). The related measures for PR was 58.8% and 50.3%, respectively (p=0.424). Males also showed significantly more ER expression than postmenopausal females; 82.3% versus 48.9% (p=0.010).
CONCLUSIONS: Breast cancer in males and females contrasted in age at diagnosis, histological type, stage, grade and ER expression which emphasize they are separate diseases with different behaviors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25684473     DOI: 10.7314/apjcp.2015.16.2.471

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  1 in total

1.  Marital Status and Survival of Patients with Hormone Receptor-Positive Male Breast Cancer: A Surveillance, Epidemiology, and End Results (SEER) Population-Based Study.

Authors:  Lei Liu; Ya-Yun Chi; An-An Wang; Yonghui Luo
Journal:  Med Sci Monit       Date:  2018-05-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.